Literature DB >> 9227815

The use of pamidronate in hypertrophic pulmonary osteoarthropathy (HPOA).

D Speden1, F Nicklason, H Francis, J Ward.   

Abstract

BACKGROUND: Hypertrophic pulmonary osteoarthropathy (HPOA) secondary to bronchogenic carcinoma can be associated with severe, disabling pain which is not always responsive to conventional treatment. AIM: To report on the use of pamidronate to control resistant pain in HPOA in three cases.
METHODS: A retrospective review of reported pain, chest X-ray and radionuclide bone scans was made.
RESULTS: Pain relief was achieved in all three cases together with reduced radiolabel uptake in two cases.
CONCLUSIONS: Pamidronate appears to be an effective therapy for HPOA. Further investigation is warranted.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9227815     DOI: 10.1111/j.1445-5994.1997.tb01983.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  4 in total

1.  Hypertrophic osteoarthropathy presenting as unilateral cellulitis with successful treatment using pamidronate disodium.

Authors:  Sebastian G Bernardo; Jason J Emer; Mark E Burnett; Marsha Gordon
Journal:  J Clin Aesthet Dermatol       Date:  2012-09

2.  Treatment of hypertrophic osteoarthropathy in the case of pulmonary metastasis secondary-to-nasopharyngeal carcinoma with zoledronic acid: an enlightening experience.

Authors:  Nikhil Sonthalia; Kabita Mukherjee; Avishek Saha; Arunansu Talukdar
Journal:  BMJ Case Rep       Date:  2012-11-11

Review 3.  Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy.

Authors:  Sheila Nguyen; Mehrnaz Hojjati
Journal:  Clin Rheumatol       Date:  2010-10-09       Impact factor: 2.980

Review 4.  Pamidronate treatment in rheumatology practice: a comprehensive review.

Authors:  Gleb Slobodin; Itzhak Rosner; Joy Feld; Doron Rimar; Michael Rozenbaum; Nina Boulman; Majed Odeh
Journal:  Clin Rheumatol       Date:  2009-08-19       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.